Developer docs
API playgroundTry for free, no card

Search company profiles

Eva Pharma

Full company profile

uuid00064u4

Namestring
Eva Pharma
Legal namestring
Eva Pharma
Websiteurl
evapharma.com
Company typeenum
Private
Founded yearint
1997
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersGîza, Egypt
HQ citystring
Gîza
HQ countrystring
Egypt
HQ regionstring
Africa
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, generic drug production, oncology treatments, insulin manufacturing, contract manufacturing services
Industry1 code
1Specialty Pharma & Biologics Distribution (GDP-compliant)
CodeHLAGAMADPrimaryYes
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
  • Biological Products, (No Disgnostic Substances)2836
Product category
Pharmaceutical Manufacturing
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Manufacturing and sale of pharmaceutical products including generics, biologics, and specialty medicines across therapeutic areas

evapharma.com
2Generic Drug Manufacturing
TypeLicensing Royalties
Description

Production of generic versions of patented drugs under voluntary licensing agreements for HIV, diabetes, and other diseases in low-to-middle-income countries

evapharma.com
3CDMO/Contract Manufacturing
TypeProfessional Services
Description

Contract development and manufacturing organization services for pharmaceutical development and commercialization in MENA region

evapharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1EVA Pharma Oncology
Description

Specialized oncology sector launched in November 2025, focusing on immunotherapy, hematology, and oncology treatments for critical medicines sustainable access.

evapharma.com
+2 more records
Core offering1 text field

Eva Pharma manufactures and distributes a portfolio of 300+ pharmaceutical products across 12 therapeutic areas including oncology, anti-infectives, cardiometabolic medicine, neuroscience, respiratory, ophthalmology, bone health, hepatology, and reproductive health. The company operates vertically integrated manufacturing from API to finished products across EU-GMP certified facilities in Egypt and Saudi Arabia, producing over 1 million packs daily for distribution to 40+ countries with focus on low-to-middle-income markets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Oncology production capacity of 22 million packs annually with 18 specialized cancer products developed
+3 more records
Product overview1 text field

EVA Pharma is a global pharmaceutical company operating as a single unified product portfolio across multiple therapeutic areas. The company manufactures and distributes pharmaceutical products through its vertically integrated operations including EU-GMP certified manufacturing facilities, research centers, and distribution networks. Key product lines include EVA Pharma Oncology (immunotherapy and oncology treatments), insulin products (glargine and human insulin), and lenacapavir (HIV treatment). The company offers CMO/CDMO contract manufacturing services and operates the mRNA Innovation Hub for vaccine development. With 300+ products in portfolio and 500+ in pipeline, the company serves 40+ countries with a focus on 12 therapeutic areas: anti-infectives, metabolic health, bone health, neuroscience, oncology, respiratory, gynecology, urology/andrology, pediatrics, ophthalmology, gastrointestinal tract, and family medicine.

Product and service14 records
1EVA Pharma Oncology
CategoryOncology Pharmaceuticals
2Insulin Glargine Injection (Glargivin)
CategoryDiabetes Pharmaceuticals
3Lenacapavir
CategoryHIV Pharmaceuticals
4mRNA Vaccines
CategoryVaccines
5Anti-infectives Portfolio
CategoryAnti-infective Pharmaceuticals
6Cardiometabolic Medicines
7Oncology Products
8Neuroscience Products
9Respiratory Products
10Ophthalmology Products
11Bone Health and Pain Management Products
12Hepatology Products
13Reproductive Health Products
14CMO/CDMO Services
CategoryContract Manufacturing Services
Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1BMZ (German Federal Ministry for Economic Cooperation and Development)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

High-level delegation visit to EVA Pharma manufacturing facilities. Visit on sidelines of WHO Global Private Sector Engagement Forum under Global Gateway framework. Focus on EVA Pharma's role as strategic African hub for pharmaceutical manufacturing and technology transfer.

2GIZ (Deutsche Gesellschaft für Internationale Zusammenarbeit)
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2026-06-01
Description

German development organization visited EVA Pharma facilities to explore localized manufacturing role in building resilient health systems. Delegation included Director General for Sustainable Development and Climate at BMZ.

3World Health Organization (WHO)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-01
Description

Collaboration on WHO pre-qualification for locally manufactured human insulin injection. Pre-qualification ensures medicines meet WHO quality standards for international procurement.

4Gilead Sciences
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-10-01
Description

Royalty-free voluntary licensing agreement for lenacapavir manufacturing and supply. EVA Pharma is the sole African licensee, authorized to manufacture API and finished products for 120 high-incidence, resource-limited countries. Includes technology transfer for sustainable accessibility to HIV treatment and prevention.

5Eli Lilly and Company
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-12-01
Description

Collaboration for local insulin manufacturing in Egypt. Lilly supplies API at reduced prices and provides pro-bono technology transfer for formulation, fill and finish of insulin vials and cartridges. First regulatory approval obtained December 2024 for insulin glargine injection. Target of 1 million people annually across 56 countries by 2030.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries11 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment2 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Eva Pharma

Pharmaceutical Manufacturingevapharma.com

Eva Pharma firmographics

Firmographics
Name
Eva Pharma
Legal name
Eva Pharma
Website
https://evapharma.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
1,001–5,000 employees
Ownership category
akta.pro rank

Eva Pharma industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
Specialty Pharma & Biologics Distribution (GDP-compliant) (HLAGAMAD)

Keywords

  • Pharmaceutical manufacturing
  • Generic drug production
  • Oncology treatments
  • Insulin manufacturing
  • Contract manufacturing services

Where Eva Pharma is headquartered

Location

Headquarters

HQ city
Gîza
HQ country
Egypt
HQ region
Africa

Offices8 records

Markets served

Eva Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Pharmaceutical Product Sales: Manufacturing and sale of pharmaceutical products including generics, biologics, and specialty medicines across therapeutic areas
  2. Generic Drug Manufacturing: Production of generic versions of patented drugs under voluntary licensing agreements for HIV, diabetes, and other diseases in low-to-middle-income countries
  3. CDMO/Contract Manufacturing: Contract development and manufacturing organization services for pharmaceutical development and commercialization in MENA region

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Eva Pharma product offering

Product offering

Core offering

Eva Pharma manufactures and distributes a portfolio of 300+ pharmaceutical products across 12 therapeutic areas including oncology, anti-infectives, cardiometabolic medicine, neuroscience, respiratory, ophthalmology, bone health, hepatology, and reproductive health. The company operates vertically integrated manufacturing from API to finished products across EU-GMP certified facilities in Egypt and Saudi Arabia, producing over 1 million packs daily for distribution to 40+ countries with focus on low-to-middle-income markets.

Product overview

EVA Pharma is a global pharmaceutical company operating as a single unified product portfolio across multiple therapeutic areas. The company manufactures and distributes pharmaceutical products through its vertically integrated operations including EU-GMP certified manufacturing facilities, research centers, and distribution networks. Key product lines include EVA Pharma Oncology (immunotherapy and oncology treatments), insulin products (glargine and human insulin), and lenacapavir (HIV treatment). The company offers CMO/CDMO contract manufacturing services and operates the mRNA Innovation Hub for vaccine development. With 300+ products in portfolio and 500+ in pipeline, the company serves 40+ countries with a focus on 12 therapeutic areas: anti-infectives, metabolic health, bone health, neuroscience, oncology, respiratory, gynecology, urology/andrology, pediatrics, ophthalmology, gastrointestinal tract, and family medicine.

Differentiator

Problem solved

Functional benefit

Brands

  • EVA Pharma Oncology: Specialized oncology sector launched in November 2025, focusing on immunotherapy, hematology, and oncology treatments for critical medicines sustainable access.
  • Limitless Naturals
  • Horus Facility

Products and services

  • EVA Pharma Oncology
  • Insulin Glargine Injection (Glargivin)
  • Lenacapavir
  • mRNA Vaccines
  • Anti-infectives Portfolio
  • Cardiometabolic Medicines
  • Oncology Products
  • Neuroscience Products
  • Respiratory Products
  • Ophthalmology Products
  • Bone Health and Pain Management Products
  • Hepatology Products
  • Reproductive Health Products
  • CMO/CDMO Services

Quantifiable outcome

  • Oncology production capacity of 22 million packs annually with 18 specialized cancer products developed
  • +3 more outcomes

Companies that use Eva Pharma

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles3 records

Eva Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Eva Pharma partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered strategic and core.

  • BMZ (German Federal Ministry for Economic Cooperation and Development)strategicStrategic or Co-development Partner · 1 June 2026High-level delegation visit to EVA Pharma manufacturing facilities. Visit on sidelines of WHO Global Private Sector Engagement Forum under Global Gateway framework. Focus on EVA Pharma's role as strategic African hub for pharmaceutical manufacturing and technology transfer.
  • GIZ (Deutsche Gesellschaft für Internationale Zusammenarbeit)strategicStrategic or Co-development Partner · 1 June 2026German development organization visited EVA Pharma facilities to explore localized manufacturing role in building resilient health systems. Delegation included Director General for Sustainable Development and Climate at BMZ.
  • World Health Organization (WHO)coreStrategic or Co-development Partner · 1 December 2024Collaboration on WHO pre-qualification for locally manufactured human insulin injection. Pre-qualification ensures medicines meet WHO quality standards for international procurement.
  • Gilead SciencescoreOEM/ Whitelabel/ Licensing Partner · 1 October 2024Royalty-free voluntary licensing agreement for lenacapavir manufacturing and supply. EVA Pharma is the sole African licensee, authorized to manufacture API and finished products for 120 high-incidence, resource-limited countries. Includes technology transfer for sustainable accessibility to HIV treatment and prevention.
  • Eli Lilly and CompanycoreStrategic or Co-development Partner · 1 December 2022Collaboration for local insulin manufacturing in Egypt. Lilly supplies API at reduced prices and provides pro-bono technology transfer for formulation, fill and finish of insulin vials and cartridges. First regulatory approval obtained December 2024 for insulin glargine injection. Target of 1 million people annually across 56 countries by 2030.

Scale indicators11 records

Recent moves9 records

Eva Pharma competitors and assessment

Company assessment

Market position

Strengths4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Eva Pharma social profiles

Digital presence

Eva Pharma compliance and trust

Trust signal

Compliance3 records

Eva Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Eva Pharma leadership team

Management profile

Number of profiles

Profiles16 records

Eva Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries11 records

Eva Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Eva Pharma M&A and investment

M&A and investment

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Eva Pharma

What does Eva Pharma do?

Eva Pharma manufactures and distributes a portfolio of 300+ pharmaceutical products across 12 therapeutic areas including oncology, anti-infectives, cardiometabolic medicine, neuroscience, respiratory, ophthalmology, bone health, hepatology, and reproductive health. The company operates vertically integrated manufacturing from API to finished products across EU-GMP certified facilities in Egypt and Saudi Arabia, producing over 1 million packs daily for distribution to 40+ countries with focus on low-to-middle-income markets.

Is Eva Pharma a public or private company?

Eva Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Eva Pharma founded?

Eva Pharma was founded in 1997. It employs 1,001 to 5,000 people.

Where is Eva Pharma based?

Eva Pharma is headquartered in Gîza, Egypt, in the Africa region.

How does Eva Pharma make money?

Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are generic Drug Manufacturing and CDMO/Contract Manufacturing.

Does Eva Pharma have an API?

No public API is recorded for Eva Pharma.

What industry is Eva Pharma in?

Eva Pharma's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGAMAD, Specialty Pharma & Biologics Distribution (GDP-compliant). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerGilead Sciences, Inc. Expands Royalty-Free Voluntary Licensing Agreements For Lenacapavir With Dr. Reddy?s Laboratories Limited, Emcure Pharmaceuticals Limited, Eva Pharma For Pharmaceutical Industries S.A.E., Ferozsons Laboratories Limited, Hetero And Mylan Laboratories LimitedGilead Sciences expanded its royalty-free voluntary licensing agreements for lenacapavir to include once-yearly PrEP for 120 high-incidence countries. The six partners—Dr. Reddy's, Emcure, Eva Pharma, Ferozsons, Hetero, and Mylan—will support manufacturing readiness and technology transfer while the Phase 3 PURPOSE 365 trial is ongoing.CairoSceneLocally Produced Insulin Now Exceeds Egypt's DemandEgypt's locally produced insulin now exceeds domestic demand, creating a surplus and reducing import reliance, according to Health Minister Khaled Abdel-Ghaffar. The minister said Egyptian factories produce 90-91% of medicine packages, though the industry still depends on imported active ingredients and packaging. The first locally manufactured long-acting insulin glargine was launched in December 2024.Tech TimesHIV Prevention Shot Posts Zero Infections in Extended Trial: Access Crisis GrowsLenacapavir's open-label extension trials showed zero new HIV infections across 4,493 person-years, with 92-96% adherence. However, funding cuts and pricing disputes block access, with Brazil excluded from generic licensing. Generic production is expected in 2027 at about $40 per person per year.openPR.comFuture Perspectives: Key Trends Shaping the Lichen Planus Market Until 2030A market report by The Business Research Company forecasts the global lichen planus market to reach $1.76 billion by 2030, growing at a CAGR of 6.8%, driven by demand for immunotherapies and digital dermatology tools. In September 2024, Eli Lilly and Company partnered with Egypt-based EVA Pharma to expand access to baricitinib (Olumiant) across 49 low- to middle-income African countries, aiming to reach an estimated 20,000 patients by 2030. Additionally, Lipella Pharmaceuticals Inc. received FDA approval in February 2025 for an expanded access program for LP-310, a liposomal tacrolimus formulation for oral lichen planus.Business Wire BlogPharmaJet® Signs Distribution Agreement with EVA Pharma to Provide Needle-free Injection Systems to Support Routine Polio Immunization in EgyptPharmaJet® announced signing a Distribution Agreement with ATR, an affiliate to EVA Pharma, to provide its Tropis® needle-free injection systems for routine polio immunization in Egypt. The agreement, signed October 30, 2025 at the CPHI meeting in Frankfurt, includes provisions for technology transfer and local manufacturing. The collaboration aims to reduce immunization costs, increase polio vaccination coverage, and broaden Egypt's medical technology manufacturing capabilities, with potential expansion to other vaccines and pandemic preparedness.ZawyaPharmaJet signs distribution agreement with EVA PharmaPharmaJet signed a Distribution Agreement with ATR, an affiliate to EVA Pharma, on October 30, 2025, at the CPHI meeting in Frankfurt. The agreement covers Tropis needle-free injection technology distribution, technology transfer, and local manufacturing, aimed at expanding needle-free vaccine access in Egypt and the broader Middle East and Africa region. The collaboration follows a July 2025 MOU between PharmaJet, Egypt's Unified Procurement Agency, and EVA Pharma, supporting Egypt's "1000 Golden Days" initiative for early childhood health and development.GlobeNewswirePharmaJet® Signs Distribution Agreement with EVA Pharma to Provide Needle-free Injection Systems to Support Routine Polio Immunization in EgyptPharmaJet signed a Distribution Agreement on October 30, 2025, with ATR, an affiliate to EVA Pharma, to provide its Tropis needle-free injection systems for routine polio immunization in Egypt. The agreement, signed at the CPHI meeting in Frankfurt, includes technology transfer and manufacturing localization provisions aimed at reducing immunization costs, increasing coverage, and addressing vaccine hesitancy. The collaboration builds on a July 2025 MOU between PharmaJet, Egypt's Unified Procurement Agency, and EVA Pharma, and supports Egypt's "1000 Golden Days" initiative for early childhood health.GlobeNewswireEVA Pharma and Zhejiang Jinhua CONBA Bio-Pharm Sign Strategic Supply AgreementEVA Pharma and Zhejiang Jinhua CONBA Bio-Pharm signed a strategic supply agreement at CPHI China 2025. The partnership aims to build a more resilient, agile, and secure pharmaceutical supply chain for emerging markets. Both companies expressed commitment to long-term supply reliability and patient access.GlobeNewswireEVA Pharma and BioPharma Town - Qiantang District, Hangzhou Sign a Strategic Cooperation AgreementEVA Pharma signed a cooperation agreement with the Chaming Qiantang Management Office in Hangzhou, establishing its eighth global office in the district. The new branch will focus on R&D and strategic supply operations in pharmaceuticals, vaccines, and biologics, leveraging Qiantang's biopharmaceutical resources.PR NewswirePorton Advanced and EVA Pharma Sign MOU to Expand CAR T-Cell Therapy Access in The Middle East and AfricaPorton Advanced Solutions and EVA Pharma signed a memorandum of understanding to collaborate on CAR T-cell therapy development and manufacturing capabilities at EVA Pharma's facilities in the Middle East and Africa. The partnership will prioritize large-scale manufacturing of lentiviral vectors for leukemia and blood cancer treatments, with Porton Advanced providing its viral vector and cell therapy manufacturing expertise while EVA Pharma contributes its regional infrastructure. By establishing localized production hubs in Egypt and Saudi Arabia, the collaboration aims to reduce treatment costs, shorten timelines, and expand access to advanced immunotherapies in underserved markets.